The short answer
Bailey reviewed long-acting amylin-related peptides as therapies for obesity and type 2 diabetes in Peptides in March 2026. Whether amylin agonism works as a standalone target, rather than only as a partner to GLP-1, is now a live question.
Key facts
- Review
- Bailey 2026, Peptides (PMID 41747885)
- Existing paired approach
- CagriSema (amylin + semaglutide)
- REDEFINE 4 outcome
- Non-inferiority not met vs tirzepatide
- Standalone candidate
- Petrelintide (PMID 41217931)
- Earlier amylin medicine
- Pramlintide
- Question
- Partner or agent in its own right
Why the question arises now
Amylin entered modern obesity development largely as a partner. Cagrilintide was paired with semaglutide to make CagriSema, and the pairing was the product. That design means the trials answer what amylin adds to GLP-1 rather than what amylin does on its own, and those are different questions.
What REDEFINE 4 did and did not test
It compared CagriSema against tirzepatide and did not demonstrate non-inferiority. That is a result about one combination at one dose pair against one comparator. It is not a verdict on amylin, because the trial never isolated the amylin contribution, a limitation this site noted when covering it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why a standalone compound answers a different question
A long-acting amylin analogue developed on its own produces evidence about amylin agonism directly. If it performs substantially, amylin is an agent in its own right; if it does not, the pairing rationale strengthens. Either outcome is informative in a way a combination trial cannot be.
The precedent, and its limits
Pramlintide reached clinical use as an amylin analogue, so the target has been engaged in humans before. It required administration with meals and its role remained adjunctive, which reflects the pharmacokinetic constraints of the era rather than a ceiling on the mechanism. Long-acting analogues change that constraint.
Why the mechanism is worth the effort
Because it is outside the incretin system. Every compound engaging GLP-1, GIP or glucagon works within one hormonal family, and combining within a family risks overlapping mechanisms. Amylin signals satiety through different receptors, so it is additive in principle rather than more of the same.
What none of this concerns
Research material. Every compound named is either a licensed medicine or an investigational one in registered trials. Nothing supplied on this site is an amylin analogue or is related to any of them.
Frequently asked questions
Did REDEFINE 4 show amylin does not work?
No. It tested one combination at one dose pair against one comparator and never isolated the amylin contribution.
Has amylin been used clinically before?
Yes. Pramlintide reached clinical use, though it required administration with meals and remained adjunctive.
Why pursue amylin rather than another incretin?
It signals satiety through receptors outside the incretin system, so it is additive rather than overlapping.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBailey CJ, Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026 (PMID 41747885)pubmed.ncbi.nlm.nih.gov
- PubMedFischer Munch H et al., Development of Petrelintide. J Med Chem 2025 (PMID 41217931)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- The Trial Where Glucose-Dependence Shows Up in Numbers2,002 randomised, 52 weeks. Hypoglycaemia 6-9% with tirzepatide against 19% with glargine - and 1-3% versus 16% without a sulfonylurea.
- TRIUMPH-4: The First Retatrutide Phase 3 to Read OutTRIUMPH-4 randomised 445 adults with obesity and knee osteoarthritis. Co-primary endpoints, two estimands, and a pain result that did not track the dose.
- VESPER: What Is Actually Registered for BerobenatideSix VESPER trials, from a 239-person Phase 2b to a 3,578-person Phase 3. Registry records, enrolment, completion dates, and which acronyms are registered.
- SOLIS-1: Testing Two Compounds and Their Combination at OnceSOLIS-1 is a Phase 2b umbrella study of an estimated 872 participants, testing an amylin analogue, an ultra-long-acting GLP-1 agonist, and both in combination.
- Reading Deal Structure as a Statement About EvidencePfizer paid $65.60 a share for Metsera plus a CVR of up to $20.65 tied to three milestones. That structure encodes how uncertain the buyer thought the data was.